Series’ Aim and Importance

In December 2024, the WHO issued a call for action, entitled “Greener Pharmaceuticals’ Regulatory Highway”, for transformative action toward a greener future in pharmaceutical manufacturing and distribution. This initiative urges global regulatory bodies and stakeholders in the pharmaceutical and healthcare industries to adopt innovative practices that prioritize sustainability and significantly reduce environmental impacts, all while upholding the highest standards of safety and efficacy.

Sustainability has become a prime focus of every organization after the declaration of the 17 interconnected Sustainable Development Goals (SDGs) by the United Nations in 2016 with an aim to build a peaceful and prosperous planet for now and the future. The pharmaceutical companies focus on all the SDGs for their contribution to environmental, social, and governance (ESG) aspects of sustainability. 

In line with the spirit of the WHO initiative, the Sustainability in Pharma series plans to review and track the progress of major pharmaceutical companies toward environmental sustainability. The environmental sustainability metrics (GHG emissions, energy usage, water usage, and waste generation) will be examined in terms of absolute and business (ratio indicator) metrics. This engaging series of articles is foundational in understanding the pharmaceutical industry’s environmental impact and presents its subsequent responses in the form of various green initiatives aimed at mitigating environmental impact and achieving environmental sustainability.

Analysis

Tracking Environmental Sustainability and GHG Targets in Pharma

The feature tracks how pharmaceutical companies report environmental sustainability and lists the targets set by these companies. Read more…

Latest Analysis

Latest Sustainability News

Interviews